Please use this identifier to cite or link to this item:
Title: Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome
Authors: Lahrouchi N.
Raju H.
Lodder E.M.
Papatheodorou E.
Ware J.S.
Papadakis M.
Tadros R.
Cole D.
Skinner J.R.
Crawford J.
Love D.R.
Pua C.J.
Soh B.Y.
Bhalshankar J.D.
Govind R.
Tfelt-Hansen J.
Winkel B.G.
van der Werf C.
Wijeyeratne Y.D.
Mellor G.
Till J.
Cohen M.C.
Tome-Esteban M.
Sharma S.
Wilde A.A.M.
Cook S.A. 
Bezzina C.R.
Sheppard M.N.
Behr E.R.
Keywords: cardiomyopathy
molecular autopsy
next-generation sequencing
unexplained sudden death
Issue Date: 2017
Publisher: Elsevier USA
Citation: Lahrouchi N., Raju H., Lodder E.M., Papatheodorou E., Ware J.S., Papadakis M., Tadros R., Cole D., Skinner J.R., Crawford J., Love D.R., Pua C.J., Soh B.Y., Bhalshankar J.D., Govind R., Tfelt-Hansen J., Winkel B.G., van der Werf C., Wijeyeratne Y.D., Mellor G., Till J., Cohen M.C., Tome-Esteban M., Sharma S., Wilde A.A.M., Cook S.A., Bezzina C.R., Sheppard M.N., Behr E.R. (2017). Utility of Post-Mortem Genetic Testing in Cases of Sudden Arrhythmic Death Syndrome. Journal of the American College of Cardiology 69 (17) : 2134-2145. ScholarBank@NUS Repository.
Abstract: Background Sudden arrhythmic death syndrome (SADS) describes a sudden death with negative autopsy and toxicological analysis. Cardiac genetic disease is a likely etiology. Objectives This study investigated the clinical utility and combined yield of post-mortem genetic testing (molecular autopsy) in cases of SADS and comprehensive clinical evaluation of surviving relatives. Methods We evaluated 302 expertly validated SADS cases with suitable DNA (median age: 24 years; 65% males) who underwent next-generation sequencing using an extended panel of 77 primary electrical disorder and cardiomyopathy genes. Pathogenic and likely pathogenic variants were classified using American College of Medical Genetics (ACMG) consensus guidelines. The yield of combined molecular autopsy and clinical evaluation in 82 surviving families was evaluated. A gene-level rare variant association analysis was conducted in SADS cases versus controls. Results A clinically actionable pathogenic or likely pathogenic variant was identified in 40 of 302 cases (13%). The main etiologies established were catecholaminergic polymorphic ventricular tachycardia and long QT syndrome (17 [6%] and 11 [4%], respectively). Gene-based rare variants association analysis showed enrichment of rare predicted deleterious variants in RYR2 (p = 5 × 10-5). Combining molecular autopsy with clinical evaluation in surviving families increased diagnostic yield from 26% to 39%. Conclusions Molecular autopsy for electrical disorder and cardiomyopathy genes, using ACMG guidelines for variant classification, identified a modest but realistic yield in SADS. Our data highlighted the predominant role of catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, especially the RYR2 gene, as well as the minimal yield from other genes. Furthermore, we showed the enhanced utility of combined clinical and genetic evaluation. © 2017 The Authors
Source Title: Journal of the American College of Cardiology
ISSN: 07351097
DOI: 10.1016/j.jacc.2017.02.046
Appears in Collections:Elements
Staff Publications

Show full item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
j.jacc.2017.02.046.pdf1.1 MBAdobe PDF




checked on Oct 22, 2020


checked on Jul 17, 2019

Page view(s)

checked on Oct 16, 2020


checked on Oct 16, 2020

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.